Eyenovia, Inc.

EYEN

US30234E1047

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 09:39:49 16/05/2024 pm IST			5-day change	1st Jan Change
0.812 ^USD	-23.40%		+1.06%	-60.91%

15/05	Transcript : Eyenovia, Inc., Q1 2024 Earnings Call, May 15, 2024
15/05	Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 12, 2023 at 01:59 am IST

Eyenovia, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 5.74 million compared to USD 7.34 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.24 a year ago.

Latest news about Eyenovia, Inc.

Transcript : Eyenovia, Inc., Q1 2024 Earnings Call, May 15, 2024	16/05
Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension	25/04	CI
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives	08/04	MT
Eyenovia Explores Wide Range of Strategic Alternatives	08/04	CI
Transcript : Eyenovia, Inc., Q4 2023 Earnings Call, Mar 18, 2024	19/03
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
North American Morning Briefing : Investors -2-	18/03	DJ
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	13/03	CI
Eyenovia Reports FDA Approval for Formosa's Post-Op Eye Inflammation, Pain Treatment	06/03	MT
US FDA approves Eyenovia's eye drug, Formosa Pharma says	05/03	RE
Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility	13/02	CI
Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Transcript : Eyenovia, Inc., Q3 2023 Earnings Call, Nov 13, 2023	14/11
Eyenovia, Inc. Appoints Michael Geltzeiler to Serve on the Board and as the Chair of the Audit Committee of the Board	10/11	CI
Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production	02/11	CI
William Blair Initiates Eyenovia at Outperform Rating	01/11	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	25/23/25	MT
Eyenovia Prices $12 Million Registered Direct Offering	25/23/25	MT
Insider Buy: Eyenovia	18/23/18	MT
Eyenovia Acquires US Rights to Eye Surgery Drug From Formosa	16/23/16	MT
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of App13007 for the Treatment of Inflammation and Pain Following Ocular Surgery	16/23/16	CI
Transcript : Eyenovia, Inc., Q2 2023 Earnings Call, Aug 10, 2023	11/23/11
Eyenovia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Eyenovia, Inc. Announces First Commercial Sale of Mydcombi	03/23/03	CI

Chart Eyenovia, Inc.

Duration

Period

More charts

Company Profile

Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.

Sector

Pharmaceuticals

Calendar

12/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Eyenovia, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.06 USD

Average target price

9.333 USD

Spread / Average Target

+780.50%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EYENOVIA, INC.	-60.91%	5.4Cr
ELI LILLY AND COMPANY	+33.19%	71TCr
NOVO NORDISK A/S	+30.77%	60TCr
JOHNSON & JOHNSON	-2.19%	37TCr
MERCK & CO., INC.	+20.23%	33TCr
ABBVIE INC.	+5.20%	29TCr
ASTRAZENECA PLC	+14.77%	24TCr
NOVARTIS AG	+9.13%	21TCr
ROCHE HOLDING AG	-3.97%	20TCr
AMGEN INC.	+9.08%	17TCr

Other Pharmaceuticals

Eyenovia, Inc.

Equities

EYEN

US30234E1047

Pharmaceuticals

Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

EPS Revisions